Vegenics Limited

Vegenics Pty Limited

Vengenics Pty Limited

Stephen A Stacker

Marc Gregory Achen

Kari Alitalo

Andrew Frederick Wilks

Megan E Baldwin

Bradley McColl

Andrew F Wilks

Described herein are pharmaceutical compositions comprising a VEGF-D polypeptide.

Pharmaceutical compositions comprising a VEGF-D polypeptide

Disclosed herein are methods of making a VEGF-D polypeptide comprising the steps of culturing a host cell transformed or transfected with a vector comprising a nucleic acid sequence encoding the VEGF-D polypeptide operably associated with a promoter sequence such that the nucleic acid sequence encoding the VEGF-D polypeptide is expressed; and isolating the VEGF-D polypeptide from the host cell or from the growth medium in which said host cell is cultured.

Methods of making VEGF-D polypeptides

Methods for activating endothelial growth factors VEGF-C or VEGF-D with plasmin, and methods of treatment comprising administering a pharmaceutical compositions comprising plasmin. Also disclosed are methods of screening for inhibitors of activation of the growth factors by plasmin, and method of treatment by blocking activation of VEGF-C/D activation by plasmin. Further disclosed are methods for screening for other proteases that activate VEGF-CD, and for inhibitors of such activation. The invention further includes inhibitors of plasmin activity and methods of treating patients in need thereof with said inhibitors.

Methods for inhibiting VEGF-D

The present invention provides VEGF-D polypeptides, which among other things stimulate endothelial cell proliferation and angiogenesis and increases vascular permeability, as well as fragments, dimers, and methods of using the same.

Growing community of inventors

Balwyn North, Australia

Stephen A Stacker